Command Palette

Search for a command to run...

Discover

Danco Requests Supreme Court Halt on 5th Circuit Abortion Pill Restrictions

Danco Requests Supreme Court Halt on 5th Circuit Abortion Pill Restrictions
Click to expand

The manufacturer of the abortion pill mifepristone asked the U.S. Supreme Court on Saturday, May 2, for emergency relief to restore access to prescriptions by mail and telehealth, one day after a federal appeals court abruptly reinstated in‑person pickup requirements nationwide.nbcnews +1 The move put medication abortion — now used in roughly two‑thirds of U.S. abortions — back before the justices in the middle of a presidential election year.cfpublic

Danco Laboratories, which markets the brand‑name version of mifepristone, filed its emergency application with Justice Samuel Alito, the conservative justice who handles urgent matters arising from the New Orleans‑based 5th U.S. Circuit Court of Appeals.nbcnews The company warned that the appeals court’s Friday order, which blocks mail delivery and telehealth prescribing of the drug while litigation continues, would cause “immediate chaos” for patients, providers, pharmacies and manufacturers that have built care models around remote access.nbcnews +1 The Biden administration is expected to support Danco’s request, echoing its stance in earlier rounds of the mifepristone fight.

How the 5th Circuit’s Ruling Alters Abortion Access

In its May 1 decision, a three‑judge 5th Circuit panel sided with Louisiana and other anti‑abortion plaintiffs, halting a 2023 Food and Drug Administration rule that allowed mifepristone to be prescribed via telehealth and shipped by mail.oregonlive +1 The order temporarily revives an older in‑person dispensing requirement, forcing patients to pick up the pill at clinics or hospitals, even in states where abortion remains legal.oregonlive

Abortion‑rights advocates and medical groups said the restrictions would hit hardest in rural areas and in states that already heavily regulate in‑clinic procedures, where telehealth had become a key route to early abortion care and miscarriage management.thehill +1 National estimates suggest medication abortion accounts for about 60–66% of U.S. abortions, with telehealth visits sharply increasing after the FDA relaxed in‑person rules during the pandemic and then permanently in 2023.cfpublic Public‑health organizations warned that the shift could push some patients into later procedures or toward unregulated sources, and strain hospitals with avoidable complications and emergency visits.wfmd

The Legal Clash Over FDA Authority and State Power

The emergency appeal arrived less than two years after the Supreme Court overturned Roe v. Wade and less than one year after the justices unanimously rejected an earlier bid to curb mifepristone access on standing grounds in FDA v. Alliance for Hippocratic Medicine.ashasexualhealth In that 2024 ruling, Justice Brett Kavanaugh wrote that federal courts are limited to “actual cases or controversies,” concluding that anti‑abortion doctors and associations had not shown the kind of concrete injury necessary to challenge the FDA’s scientific judgments.ashasexualhealth

The new dispute stems from a different lawsuit, spearheaded by Louisiana, that frames the issue as a clash between federal drug policy and state abortion bans.news3lv Louisiana argues that mail‑order and telehealth prescriptions allow out‑of‑state providers to circumvent its abortion restrictions, and that the FDA overstepped by loosening safeguards without adequate consideration of safety risks.news3lv Danco and the federal government counter that decades of clinical‑trial data and post‑marketing surveillance show mifepristone is safe and effective, with serious complications extremely rare, and that judges should not second‑guess the agency’s expert risk‑management decisions.dailyherald They also warn that allowing a single appeals court to upend nationwide drug rules could encourage similar challenges to other controversial medications.

The Bigger Picture

The Supreme Court could act within days, issuing a brief administrative stay to keep current rules in place while the justices study the filings, or it could allow the 5th Circuit restrictions to take effect while the case proceeds.nbcnews +1 Either path will shape not only how quickly millions of Americans can access medication abortion, but also how far federal courts are willing to go in second‑guessing the FDA and in refereeing conflicts between national drug standards and divergent state abortion laws. With reproductive rights already a central campaign issue, the court’s next move is likely to reverberate well beyond the legal community.

nbcnews CNN, May 2, 2026
thehill New York Times, May 2, 2026
cfpublic Guttmacher Institute data cited in major news outlets, May 2026
oregonlive CNN, May 1, 2026
news3lv 5th Circuit order and coverage in Washington Post, May 1, 2026
wfmd Statements from medical and reproductive‑rights groups reported May 1–2, 2026
ashasexualhealth U.S. Supreme Court, FDA v. Alliance for Hippocratic Medicine (2024)
dailyherald Danco Supreme Court merits brief and FDA clinical review excerpts